目前,我国推行的医药卫生体制改革正在不断深入,新医改政策致力于大力推进社区和基层医疗机构的建设,并建立覆盖城乡居民的基本医保体系,药品加成政策的改革与实行药品零差率销售,让规模小、不具备竞争实力的单体药店面临利润空间的挤压。在此种情况下,单体药店为求生存,各想其招,最直接的是降低成本,如硬件不投入、不聘用专业人员,从外埠购药等,大大增加了药品监管风险,在这种新形势下如何加强对单体药店的风险监管是摆在药监部门面前的一个难题。日前,笔者就此问题对顺义区的单体药店的风险监管情况进行了调查。 At present, the reform of the medical and health system in our country is deepening. The new medical reform policy is devoted to vigorously promoting the construction of community and grass-roots medical institutions and establishing a basic medical insurance system covering both urban and rural residents. The reform and implementation of the drug addition rate policy zero rate Sales, so that small-scale, do not have the competitive strength of the single drug store is squeezed profit margins. In this case, the single drugstore in order to survive, think their trick, the most direct is to reduce costs, such as the hardware does not invest, do not hire professionals, purchasing drugs from other provinces, greatly increased the risk of drug regulation, in this Under the new situation, how to strengthen the supervision of the risk of a single drugstore is a problem that the drug regulatory department faces. Recently, the author of this issue of Shunyi District, a single pharmacy risk supervision conducted a survey.